Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × Celecoxib × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Unspecified Adult Solid Tumor, Protocol Specific 4 Sarcoma 4 Colorectal Neoplasms 4 Neoplasms 3 Neoplasm Metastasis 3 Colonic Neoplasms 3 Thymoma 2 Rectal Neoplasms 2 Primary Myelofibrosis 2 Myeloproliferative Disorders 2 Multiple Myeloma 2 Mesothelioma, Malignant 2 Melanoma 2 Leukemia, Myelomonocytic, Chronic 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Thrombocythemia, Essential 1 Solid Tumor, Adult 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Polycythemia Vera 1

Interventions

Cyclophosphamide 39 fludarabine 28 Dexamethasone 23 venetoclax 19 Cytarabine 17 Rituximab 14 pembrolizumab 12 fludarabine phosphate 12 Filgrastim 12 Etoposide 11 Gemcitabine 10 Lenalidomide 9 Granulocyte Colony-Stimulating Factor 9 carfilzomib 8 Vincristine 8 Topotecan 8 Interleukin-2 8 Decitabine 8 pomalidomide 7 Nivolumab 7 Melphalan 7 Everolimus 7 Doxorubicin 7 Calcium Dobesilate 7 Bortezomib 7 Azacitidine 7 Vorinostat 6 Methotrexate 6 Injections 6 Carboplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02115074 2026-03-18

FLUVABREX

Centre Oscar Lambret

Phase 1 Completed

Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡